^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    hydroxychloroquine

    Company:
    Generic mfg.
    Drug class:
    Immunomodulator
    Related drugs:
    1d
    HYDROSAPL: HYDROxychloroquine in Syndrome Primary AntiPhospholipid (clinicaltrials.gov)
    P2, N=0, Withdrawn, Assistance Publique - Hôpitaux de Paris | N=110 --> 0 | Recruiting --> Withdrawn
    Enrollment change • Trial withdrawal
    |
    hydroxychloroquine
    1d
    the HOPE trial: Binimetinib and Hydroxychloroquine in Treating Patients With KRAS Mutant Metastatic Pancreatic Cancer (clinicaltrials.gov)
    P1, N=34, Completed, M.D. Anderson Cancer Center | Active, not recruiting --> Completed | Trial completion date: Dec 2026 --> Mar 2026 | Trial primary completion date: Dec 2026 --> Mar 2026
    Trial completion • Trial completion date • Trial primary completion date
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation
    |
    Mektovi (binimetinib) • hydroxychloroquine
    2d
    Sarcoidosis-Induced Hypercalcemia in a Patient With Multiple Endocrine Neoplasia Type 2A (MEN2A) Syndrome Harboring the C609Y REarranged During Transfection (RET) Mutation. (PubMed, AACE Endocrinol Diabetes)
    Patient was managed acutely with calcitonin and was started on prednisone and hydroxychloroquine. The co-occurrence of both MEN 2A and sarcoidosis is rare, adding an unexpected layer of complexity to the diagnosis. The rarity of sarcoidosis co-occurring with MEN 2A highlights the importance of considering a broad differential diagnosis, even in patients with known genetic syndromes, to ensure accurate management.
    Journal
    |
    RET (Ret Proto-Oncogene)
    |
    RET mutation
    |
    prednisone • hydroxychloroquine
    5d
    Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer (clinicaltrials.gov)
    P1, N=62, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2026 --> Mar 2027
    Trial completion date
    |
    MK-2206 • hydroxychloroquine
    9d
    PRIMERA001: Comparing the effectiveness of our tailor-made management approach with routine care from a clinical, patient's as well as an economic point of view. Tailoring of treatment is done by taking the presence of autoantibodies and the quick response to glucocorticoids and JAK inhibitors into account. (2024-511530-12-01)
    P4, N=300, Active, not recruiting, Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC) | Not yet recruiting --> Active, not recruiting
    Enrollment closed
    |
    hydroxychloroquine • Simponi (golimumab) • leflunomide • methylprednisolone acetate
    11d
    CHAPPII: Safety and Effect on Pain and Function According to RAPID-3 of IHL-675A in Patients With Rheumatoid Arthritis (clinicaltrials.gov)
    P2, N=20, Terminated, Incannex Healthcare Ltd | Suspended --> Terminated; Recruitment challenges
    Trial termination
    |
    hydroxychloroquine • Epidiolex (cannabidiol)
    14d
    The Efficacy and Safety of Anti-inflammation Treatment (Hirudoid Introduction Followed by Yellow Light Therapy) Combined With Tofacitinib and Doxycycline in Chinese Adult Patients With Mild to Moderate Erythematous Telangiectatic Rosacea (clinicaltrials.gov)
    P=N/A, N=186, Recruiting, The Fourth Affiliated Hospital of Zhejiang University School of Medicine | Not yet recruiting --> Recruiting
    Enrollment open
    |
    hydroxychloroquine • tofacitinib
    18d
    Hydroxychloroquin (HCQ) in chILD of Genetic Defect (clinicaltrials.gov)
    P=N/A, N=25, Completed, Children's Hospital of Fudan University | Recruiting --> Completed | Trial completion date: Jul 2026 --> Mar 2026
    Trial completion • Trial completion date
    |
    NKX2-1 (NK2 Homeobox 1) • ABCA3 (ATP Binding Cassette Subfamily A Member 3) • NPC1 (NPC Intracellular Cholesterol Transporter 1)
    |
    hydroxychloroquine
    22d
    Hydroxychloroquine alleviates cyclophosphamide-induced premature ovarian failure by attenuating granulosa cell senescence and modulating the mtDNA-cGAS pathway. (PubMed, NPJ Aging)
    HCQ attenuated CTX-induced cellular senescence, stabilized mitochondrial membranes, decreased reactive oxygen species (ROS) production and mitochondrial DNA (mtDNA) leakage, inhibited the cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) signaling pathway, and suppressed the expression of senescence-associated secretory phenotype (SASP) factors. Collectively, our preclinical findings demonstrate that HCQ alleviates CTX-induced POF, which is associated with the mitigation of granulosa cell senescence and modulation of the mtDNA-cGAS signaling pathway.
    Journal
    |
    STING (stimulator of interferon response cGAMP interactor 1) • CGAS (Cyclic GMP-AMP Synthase)
    |
    cyclophosphamide • hydroxychloroquine
    26d
    AIPH-TB-RCT-P2: AIPH-TB: AI-Optimised Pyrazinamide-Hydroxychloroquine vs Standard RIPE for Drug-Sensitive Pulmonary Tuberculosis - A Phase II RCT (clinicaltrials.gov)
    P2, N=200, Not yet recruiting, Ministry of Health, Saudi Arabia
    New P2 trial
    |
    CD4 (CD4 Molecule)
    |
    hydroxychloroquine
    1m
    PaTcH Study: A Phase 2 Study of Trametinib and Hydroxychloroquine in Patients With Metastatic Refractory Pancreatic Cancer (clinicaltrials.gov)
    P2, N=22, Active, not recruiting, Cancer Trials Ireland | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Mekinist (trametinib) • hydroxychloroquine